

Jeffrey M Trent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7268419/publications.pdf>

Version: 2024-02-01

24
papers

3,094
citations

489802

18
h-index

685536

24
g-index

26
all docs

26
docs citations

26
times ranked

5289
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of genomicâ€­guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for highâ€­risk neuroblastoma. <i>Cancer Reports</i> , 2022, 5, e1616.	0.6	5
2	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	1.1	5
3	The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. <i>Oncotarget</i> , 2021, 12, 1836-1847.	0.8	1
4	Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing. <i>Nature Biotechnology</i> , 2021, 39, 1151-1160.	9.4	39
5	Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. <i>Cancer Research</i> , 2021, 81, 5818-5832.	0.4	10
6	HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases. <i>Cancer Research</i> , 2020, 80, 3009-3022.	0.4	19
7	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthaseâ€­Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	3.2	21
8	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 1932-1943.	3.2	51
9	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2767-2779.	1.9	50
10	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	1.5	56
11	The histone methyltransferase <i>EZH2</i> is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2017, 242, 371-383.	2.1	78
12	Integrated genomic analyses reveal frequent <i>TERT</i> aberrations in acral melanoma. <i>Genome Research</i> , 2017, 27, 524-532.	2.4	122
13	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. <i>Gynecologic Oncology</i> , 2016, 141, 454-460.	0.6	85
14	Dual loss of the <i>SWI</i> / <i>SNF</i> complex <i>ATPases SMARCA4</i> / <i>BRG1</i> and <i>SMARCA2</i> / <i>BRM</i> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016, 238, 389-400.	2.1	169
15	Perspectives from manâ€™s best friend: National Academy of Medicineâ€™s Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5.	5.8	108
16	Feasibility of implementing molecularâ€­guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. <i>Cancer Medicine</i> , 2015, 4, 871-886.	1.3	26
17	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Nonâ€­V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	1.9	25
18	Loss of the tumor suppressor <i>SMARCA4</i> in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). <i>Rare Diseases (Austin, Tex)</i> , 2014, 2, e967148.	1.8	40

#	ARTICLE	IF	CITATIONS
19	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. <i>Clinical Cancer Research</i> , 2014, 20, 4200-4209.	3.2	127
20	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. <i>Nature Genetics</i> , 2014, 46, 427-429.	9.4	298
21	Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials. <i>PLoS ONE</i> , 2014, 9, e90028.	1.1	33
22	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. <i>Nature Genetics</i> , 2012, 44, 165-169.	9.4	170
23	The Gene Topography of Cancer. <i>Science</i> , 2007, 318, 1079-1080.	6.0	5
24	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003, 33, 19-20.	9.4	1,547